@article{JGO128,
author = {Ikechukwu Akunyili and Monica T Garcia-Buitrago and Jessica MacIntyre and Joe Levi and Caio M Rocha Lima},
title = {Sustained response to FOLFOX and Bevacizumab in metastatic bronchial carcinoid – A case report and review of the literature},
journal = {Journal of Gastrointestinal Oncology},
volume = {2},
number = {2},
year = {2011},
keywords = {},
abstract = {A 65 year old male with bronchial carcinoid developed diffuse liver metastases seventeen months after curative resection of a solitary liver metastasis. Treatment with modified (m) FOLFOX 6 (5-FU, 400mg/m2 bolus infusion, followed by Leucovorin 400 mg/m2 and Oxaliplatin 85 mg/m2 given in “Y” over 2 hours followed by 5 FU 2,400 mg/m2 continuous infusion over 46 hours) plus Bevacizumab and Octreotide were given after progression on Octreotide alone. It resulted in sustained partial response. To our knowledge, this is the first reported case demonstrating activity of FOLFOX and Bevacizumab in metastatic bronchial carcinoid. The response and clinical benefit of FOLFOX with Bevacizumab in this case of metastatic bronchial carcinoid suggest that this treatment is active and should be further studied in patients with metastatic and unresectable bronchial carcinoid tumors.},
issn = {2219-679X}, url = {https://jgo.amegroups.org/article/view/128}
}